JP7251033B2 - ドネペジル経皮送達システム - Google Patents

ドネペジル経皮送達システム Download PDF

Info

Publication number
JP7251033B2
JP7251033B2 JP2019504001A JP2019504001A JP7251033B2 JP 7251033 B2 JP7251033 B2 JP 7251033B2 JP 2019504001 A JP2019504001 A JP 2019504001A JP 2019504001 A JP2019504001 A JP 2019504001A JP 7251033 B2 JP7251033 B2 JP 7251033B2
Authority
JP
Japan
Prior art keywords
donepezil
weight
layer
drug reservoir
adhesive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019504001A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019523270A (ja
JP2019523270A5 (enExample
Inventor
ウン ス リ，
アミット ケー． ジェイン，
パーミンダー シン，
Original Assignee
コリウム， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コリウム， エルエルシー filed Critical コリウム， エルエルシー
Publication of JP2019523270A publication Critical patent/JP2019523270A/ja
Publication of JP2019523270A5 publication Critical patent/JP2019523270A5/ja
Priority to JP2022106083A priority Critical patent/JP2022121629A/ja
Application granted granted Critical
Publication of JP7251033B2 publication Critical patent/JP7251033B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/0008—Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
    • C08K5/0016—Plasticisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019504001A 2016-07-27 2017-07-26 ドネペジル経皮送達システム Active JP7251033B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022106083A JP2022121629A (ja) 2016-07-27 2022-06-30 ドネペジル経皮送達システム

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201662367542P 2016-07-27 2016-07-27
US201662367502P 2016-07-27 2016-07-27
US62/367,542 2016-07-27
US62/367,502 2016-07-27
US201662423133P 2016-11-16 2016-11-16
US62/423,133 2016-11-16
US201762444763P 2017-01-10 2017-01-10
US201762444745P 2017-01-10 2017-01-10
US62/444,745 2017-01-10
US62/444,763 2017-01-10
US201762457794P 2017-02-10 2017-02-10
US62/457,794 2017-02-10
US201762504391P 2017-05-10 2017-05-10
US201762504408P 2017-05-10 2017-05-10
US62/504,391 2017-05-10
US62/504,408 2017-05-10
PCT/US2017/044050 WO2018022817A1 (en) 2016-07-27 2017-07-26 Donepezil transdermal delivery system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022106083A Division JP2022121629A (ja) 2016-07-27 2022-06-30 ドネペジル経皮送達システム

Publications (3)

Publication Number Publication Date
JP2019523270A JP2019523270A (ja) 2019-08-22
JP2019523270A5 JP2019523270A5 (enExample) 2020-08-20
JP7251033B2 true JP7251033B2 (ja) 2023-04-04

Family

ID=59523314

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2019504000A Active JP7071330B2 (ja) 2016-07-27 2017-07-26 炭酸水素ナトリウムのｉｎ ｓｉｔｕ変換で促進されたアミン薬物の経皮送達
JP2019504001A Active JP7251033B2 (ja) 2016-07-27 2017-07-26 ドネペジル経皮送達システム
JP2019503974A Active JP7153010B2 (ja) 2016-07-27 2017-07-26 塩薬物のｉｎ ｓｉｔｕでの塩から中性の薬物変換による、低溶解度または不安定非イオン化中性薬物の経皮配合物および送達方法
JP2022076575A Pending JP2022093707A (ja) 2016-07-27 2022-05-06 炭酸水素ナトリウムのｉｎ ｓｉｔｕ変換で促進されたアミン薬物の経皮送達
JP2022106083A Pending JP2022121629A (ja) 2016-07-27 2022-06-30 ドネペジル経皮送達システム
JP2022124683A Pending JP2022140751A (ja) 2016-07-27 2022-08-04 塩薬物のｉｎ ｓｉｔｕでの塩から中性の薬物変換による、低溶解度または不安定非イオン化中性薬物の経皮配合物および送達方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019504000A Active JP7071330B2 (ja) 2016-07-27 2017-07-26 炭酸水素ナトリウムのｉｎ ｓｉｔｕ変換で促進されたアミン薬物の経皮送達

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019503974A Active JP7153010B2 (ja) 2016-07-27 2017-07-26 塩薬物のｉｎ ｓｉｔｕでの塩から中性の薬物変換による、低溶解度または不安定非イオン化中性薬物の経皮配合物および送達方法
JP2022076575A Pending JP2022093707A (ja) 2016-07-27 2022-05-06 炭酸水素ナトリウムのｉｎ ｓｉｔｕ変換で促進されたアミン薬物の経皮送達
JP2022106083A Pending JP2022121629A (ja) 2016-07-27 2022-06-30 ドネペジル経皮送達システム
JP2022124683A Pending JP2022140751A (ja) 2016-07-27 2022-08-04 塩薬物のｉｎ ｓｉｔｕでの塩から中性の薬物変換による、低溶解度または不安定非イオン化中性薬物の経皮配合物および送達方法

Country Status (10)

Country Link
US (13) US9993466B2 (enExample)
EP (3) EP3490540A1 (enExample)
JP (6) JP7071330B2 (enExample)
KR (9) KR102406536B1 (enExample)
CN (5) CN109789105B (enExample)
AU (7) AU2017302306A1 (enExample)
CA (2) CA3032044C (enExample)
MX (2) MX394249B (enExample)
SG (1) SG11201900692WA (enExample)
WO (3) WO2018022817A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016105499A1 (en) 2014-12-23 2016-06-30 Intellectual Property Associates, Llc Methods and formulations for transdermal administration
WO2017083920A1 (en) * 2015-11-18 2017-05-26 Commonwealth Scientific And Industrial Research Organisation Rice grain with thickened aleurone
IL303255A (en) 2015-12-30 2023-07-01 Corium Inc Systems and methods for long term transdermal administration
JP7174632B2 (ja) 2016-06-23 2022-11-17 コリウム， インコーポレイテッド 親水性ドメインおよび疎水性ドメインならびに処置剤との接着剤マトリックス
KR102508993B1 (ko) 2016-07-27 2023-03-10 코리움, 인크. 메만틴 경피 송달 시스템
KR102406536B1 (ko) 2016-07-27 2022-06-08 코리움, 인크. 도네페질 경피 전달 시스템
CA3071007A1 (en) * 2017-07-26 2019-01-31 Corium, Inc. Transdermal delivery system with a microporous membrane having solvent-filled pores
WO2019055880A2 (en) 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. METHOD OF ADMINISTRATION AND TREATMENT
AU2018392686A1 (en) 2017-12-20 2020-07-09 Corium Pharma Solutions, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
KR102710072B1 (ko) * 2018-08-31 2024-09-24 에스케이케미칼 주식회사 장기 투여용 리바스티그민 패취
KR102823139B1 (ko) * 2018-08-31 2025-06-19 에스케이케미칼 주식회사 장기 투여용 리바스티그민 패취
KR102115102B1 (ko) 2018-12-21 2020-05-26 동아에스티 주식회사 안정화된 도네페질 함유 경피 흡수제제
KR102372630B1 (ko) * 2019-05-15 2022-03-14 주식회사 대웅제약 고함량의 도네페질 또는 그의 염을 포함하는 경피흡수제제
US11101101B2 (en) * 2019-05-15 2021-08-24 Fei Company Laser-based phase plate image contrast manipulation
CA3154505A1 (en) * 2019-10-24 2021-04-29 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of fingolimod
EP4066829A4 (en) * 2019-11-26 2023-12-27 Hisamitsu Pharmaceutical Co., Inc. Method for improving holding power of adhesive agent layer in ropinirole-containing transdermal patch, and ropinirole-containing transdermal patch having improved holding power
US20230357787A1 (en) * 2019-12-18 2023-11-09 Pioneer Hi-Bred International, Inc. Compositions and methods for improving grain yield in plants
US20230123388A1 (en) * 2020-04-14 2023-04-20 Glanis Pharmaceuticals, Inc. Transdermal and/or topical delivery system comprising hydroxychloroquine and/or chloroquine
JP2022044038A (ja) * 2020-09-04 2022-03-16 株式会社大石膏盛堂 ドネペジル含有経皮吸収液剤およびその製造方法
CN112656778A (zh) * 2020-12-28 2021-04-16 广东红珊瑚药业有限公司 一种压敏胶基质以及一种贴剂
US12270039B2 (en) * 2021-05-14 2025-04-08 Board Of Trustees Of Southern Illinois University Compositions and methods to increase oleic acid content in soybeans
US12270040B2 (en) * 2021-05-27 2025-04-08 Board Of Trustees Of Southern Illinois University Soybean lines with low saturated fatty acid and high oleic acid contents
CR20240001A (es) * 2021-07-08 2024-05-22 Monsanto Technology Llc Proteínas inhibidoras de insectos novedosas
WO2025103446A1 (zh) * 2023-11-16 2025-05-22 宜昌人福药业有限责任公司 含有多奈哌齐的透皮贴剂及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007129427A1 (ja) 2006-05-08 2007-11-15 Teikoku Seiyaku Co., Ltd. 抗認知症薬物の経皮吸収製剤
JP2007302582A (ja) 2006-05-09 2007-11-22 Hisamitsu Pharmaceut Co Inc ドネペジル経皮吸収型製剤
WO2008066179A1 (en) 2006-12-01 2008-06-05 Nitto Denko Corporation Percutaneous absorption preparation
JP2011513447A (ja) 2008-03-11 2011-04-28 エルテーエス ローマン テラピー−ジステーメ アーゲー 安定化された膜を有する経皮治療システム
JP2013528631A (ja) 2010-06-17 2013-07-11 エルテーエス ローマン テラピー−ジステーメ アーゲー メマンチンの経皮投与
JP2014502639A (ja) 2011-01-12 2014-02-03 タイワン バイオテック カンパニー リミテッド ドネペジル経皮吸収型パッチ及びアルツハイマー病の治療方法

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
NL134681C (enExample) 1966-04-26
US3546141A (en) 1966-08-08 1970-12-08 Mc Donnell Douglas Corp Phosphorus-nitrogen polymers and process
CA974518A (en) 1972-04-20 1975-09-16 Merz And Co. Procedure for the manufacture of 1,3,5 trisubstituted adamantan compounds
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
ATE45735T1 (de) 1984-12-22 1989-09-15 Thomae Gmbh Dr K Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel.
US4880633A (en) 1986-03-12 1989-11-14 Merck & Co., Inc. Transdermal drug delivery system
US4797284A (en) * 1986-03-12 1989-01-10 Merck & Co., Inc. Transdermal drug delivery system
DE3634016A1 (de) 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4781924A (en) 1987-11-09 1988-11-01 Alza Corporation Transdermal drug delivery device
US4837027A (en) 1987-11-09 1989-06-06 Alza Corporation Transdermal drug delivery device
US4849224A (en) 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
US5026556A (en) 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
DE10299048I2 (de) 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
DE3913734C2 (de) * 1989-04-26 1998-08-20 Roehm Gmbh Verwendung einer wäßrigen Hauthaftkleberlösung zur Herstellung einer mit Wasser leicht abwaschbaren Klebschicht
MY115126A (en) * 1990-04-27 2003-04-30 Seikisui Chemical Co Ltd Percutaneously absorbable eperisone or tolperisone preparation.
US5252588A (en) * 1990-04-27 1993-10-12 Sekisui Kagaku Kogyo Kabushiki Kaisha Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation
EP0540623B1 (en) 1990-07-23 1994-09-14 Alza Corporation Oral osmotic device for delivering nicotine
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5123900A (en) 1991-08-16 1992-06-23 Bertek, Inc. Moisture permeable double disk
JPH06199659A (ja) 1992-10-28 1994-07-19 Hisamitsu Pharmaceut Co Inc 経皮治療用装置
DE4310012A1 (de) * 1993-03-27 1994-09-29 Roehm Gmbh Dermales therapeutisches System aus einer schmelzfähigen Poly(meth)acrylat-Mischung
US5424077A (en) 1993-07-13 1995-06-13 Church & Dwight Co., Inc. Co-micronized bicarbonate salt compositions
JP3483148B2 (ja) * 1994-04-21 2004-01-06 久光製薬株式会社 経皮投与基剤組成物およびその薬剤組成物
CA2198390C (en) 1994-09-14 2009-08-11 James E. Garbe Matrix for transdermal drug delivery
US5635203A (en) * 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
CA2208132A1 (en) 1994-12-21 1996-06-27 Theratech, Inc. Transdermal delivery system with adhesive overlay and peel seal disc
AU6032696A (en) 1995-06-07 1996-12-30 Cygnus Therapeutic Systems Pressure sensitive acrylate adhesive composition cross-linke d with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group
DE19531342B4 (de) 1995-08-25 2007-11-29 Merz Pharma Gmbh & Co. Kgaa Verwendung von Aminoadamantan-Verbindungen als Immunregulatoren
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5958919A (en) 1996-09-20 1999-09-28 Washington University Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
AU4990797A (en) 1996-10-24 1998-05-15 Alza Corporation Permeation enhancers for transdermal drug delivery compositions, devices, and methods
CN1174031A (zh) * 1997-04-23 1998-02-25 谢先运 双氯芬酸钠透皮控释贴膏
US5866585A (en) 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US20040018241A1 (en) * 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6193993B1 (en) 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
JP4205778B2 (ja) * 1998-04-17 2009-01-07 久光製薬株式会社 貼付製剤
DE19820999A1 (de) 1998-05-11 1999-11-18 Lohmann Therapie Syst Lts Laminat zum Aufbringen auf einen Akzeptor
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
US20020192243A1 (en) * 1999-12-16 2002-12-19 Tsung-Min Hsu Transdermal and topical administration of drugs for the treatment of Alzheimer's disease using basic enhancers
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
EP1331929A1 (en) * 2000-11-06 2003-08-06 Samyang Corporation Transdermal drug delivery system with improved water absorbability and adhesion properties
WO2002038139A1 (en) * 2000-11-07 2002-05-16 Hisamitsu Pharmaceutical Co., Inc. Pharmaceutical preparation of percutaneous absorption type
JP4850346B2 (ja) * 2001-03-15 2012-01-11 救急薬品工業株式会社 粘膜貼付剤
CA2445086C (en) 2001-05-01 2008-04-08 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions
NZ531785A (en) 2001-08-20 2007-03-30 Maiken Nedergaard Treatment of glial tumors with ionotropic glutamate receptor antagonists
ATE352292T1 (de) 2001-09-04 2007-02-15 Trommsdorff Arzneimittel Pflaster mit sertaconazol zur behandlung von nagelfunktionsstörungen und erkrankungen
EP1437130A4 (en) * 2001-10-17 2009-08-26 Hisamitsu Pharmaceutical Co PERCUTANEOUS ABSORPTION PREPARATIONS
ITMI20012827A1 (it) * 2001-12-28 2003-06-28 Fidia Farmaceutici Formulazioni adesive transdermiche di diclofenac sodico
US7273619B2 (en) 2002-01-17 2007-09-25 Samyang Corporation Transdermal composition of an antivomiting agent
AU2003274353B2 (en) 2002-10-24 2007-04-05 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
EP1670433B1 (en) 2003-10-10 2011-11-23 Antares Pharma IPL AG Transdermal pharmaceutical formulation for minimizing skin residues
CN1886105A (zh) * 2003-10-14 2006-12-27 德马全兹股份有限公司 经增强的亲水药物的经皮给药
WO2005079779A1 (en) 2003-10-22 2005-09-01 Merz Pharma Gmbh & Co. Kgaa THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES
JP2007516738A (ja) 2003-10-23 2007-06-28 トランスワン インコーポレイティッド 背骨に対して最小の侵入処理を行うための道具及び道具キット
JP2007512339A (ja) 2003-11-21 2007-05-17 メモリー・ファーマシューティカルズ・コーポレイション 記憶障害の処置における（＋）−イソプロピル２−メトキシエチル４−（２−クロロ−３−シアノ−フェニル）−１，４−ジヒドロ−２，６−ジメチル−ピリジン−３，５−ジカルボキシラートの使用
US7176185B2 (en) 2003-11-25 2007-02-13 Tsrl, Inc. Short peptide carrier system for cellular delivery of agent
US7658945B2 (en) 2004-02-17 2010-02-09 Transcept Pharmaceuticals, Inc. Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US7670838B2 (en) 2004-05-24 2010-03-02 The Board Of Trustees Of The Leland Stanford Junior University Coupling of excitation and neurogenesis in neural stem/progenitor cells
US20080038328A1 (en) 2004-05-28 2008-02-14 Naruhito Higo Pasting Preparation
TW200616608A (en) 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
ES2596809T3 (es) 2004-10-08 2017-01-12 Noven Pharmaceuticals, Inc. Dispositivo de administración transdérmica de fármacos que incluye un refuerzo oclusivo
EP1661560B1 (en) 2004-11-22 2008-11-05 Hisamitsu Pharmaceutical Co., Inc. Transdermal patch comprising a melting point lowering agent
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
MX2007007301A (es) 2005-01-11 2008-02-11 Teva Pharm Fine Chemicals Srl Polimorfos de clorhidrato de memantina.
WO2006082728A1 (ja) * 2005-02-04 2006-08-10 Hisamitsu Pharmaceutical Co., Inc. 経皮吸収貼付剤
US20060188558A1 (en) 2005-02-18 2006-08-24 Mylan Technologies, Inc. Transdermal systems having control delivery system
EP1874282B1 (en) 2005-04-06 2010-09-15 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
US7888422B2 (en) 2005-11-09 2011-02-15 Mylan Technologies Inc. Long-wearing removable pressure sensitive adhesive
ATE468219T1 (de) * 2006-03-28 2010-06-15 Amcor Flexibles Transpac B V B Für aromaverbindungen undurchlässige, halogenfreie mehrschichtfolie
CN1895242B (zh) * 2006-04-13 2011-08-31 沈阳药科大学 双氯芬酸盐的透皮贴剂及制备方法
IL175338A0 (en) 2006-05-01 2006-09-05 Biota Ltd Orally administrable films and preparation thereof
TW200815045A (en) * 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
US9248104B2 (en) 2006-08-17 2016-02-02 Core Tech Solutions, Inc. Transdermal methods and systems for treating Alzheimer's disease
US20080107719A1 (en) 2006-11-08 2008-05-08 Sukhon Likitlersuang Transdermal drug delivery system
EP2098235B1 (en) * 2006-12-01 2013-08-21 Nitto Denko Corporation Method for prevention of discoloration with time of donepezil-containing skin adhesive preparation
EP2098233A4 (en) 2006-12-01 2012-03-21 Nitto Denko Corp PREPARATION OF SKIN ADHESIVE COMPRISING DERESEPZIL STABILIZED
JP5403948B2 (ja) 2007-06-07 2014-01-29 久光製薬株式会社 メマンチン含有経皮吸収製剤
EP2167002B1 (en) 2007-07-10 2016-04-20 Agile Therapeutics, Inc. Dermal delivery device with in situ seal
US9017301B2 (en) * 2007-09-04 2015-04-28 Mylan Technologies, Inc. Transdermal drug delivery systems comprising a coated release liner
JP2009203213A (ja) * 2008-02-28 2009-09-10 Kosumedei Seiyaku Kk 経皮吸収医薬組成物
KR101454362B1 (ko) 2008-03-24 2014-10-23 아이큐어 주식회사 도네페질을 유효성분으로 함유하는 치매 치료용경피흡수제제
EP2111857A1 (de) 2008-04-25 2009-10-28 Acino AG Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff hiervon
US20090291127A1 (en) 2008-05-21 2009-11-26 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
AR074062A1 (es) 2008-10-31 2010-12-22 Lexicon Pharmaceuticals Inc Agonistas del receptor s1p para el tratamiento de la malaria cerebral y forma farmaceutica
US20100178037A1 (en) 2009-01-12 2010-07-15 Te-Wei Chen Display apparatus, video generation apparatus, and method thereof
CA2751884C (en) * 2009-01-14 2018-09-25 Corium International, Inc. Transdermal administration of tamsulosin
US8512742B2 (en) 2009-05-01 2013-08-20 Hisamitsu Pharmaceutical Co., Inc. Transdermal preparation
WO2011034323A2 (en) 2009-09-16 2011-03-24 Samyang Corporation Transdermal delivery system, method for manufacturing the same, and transdermal delivery method using the system
KR101734602B1 (ko) 2009-10-21 2017-05-11 데이고꾸세이약꾸가부시끼가이샤 도네페질 함유 경피 흡수형 제제
CN102048678A (zh) * 2009-10-30 2011-05-11 北京隆旗生物科技有限公司 一种奥昔布宁的透皮吸收制剂及其制备方法与药物应用
GB0921481D0 (en) 2009-12-08 2010-01-20 Vectura Ltd Process and product
JP2012236773A (ja) * 2009-12-16 2012-12-06 Goto Takeshi 抗認知症薬物の経皮吸収製剤
CA2785639A1 (en) 2009-12-30 2011-07-07 Novartis Ag Melt extruded nicotine thin strips
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
JP5615898B2 (ja) * 2010-02-24 2014-10-29 久光製薬株式会社 貼付剤
US20110244023A1 (en) * 2010-03-30 2011-10-06 Phosphagenics Limited Transdermal delivery patch
EP2564848B1 (en) 2010-04-28 2015-09-02 Hisamitsu Pharmaceutical Co., Inc. Transdermally absorbable donepezil-containing preparation
WO2011146583A2 (en) 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
NZ605352A (en) * 2010-06-30 2013-10-25 Nal Pharmaceuticals Ltd Process for producing glycosaminoglycans
US20140370076A1 (en) 2010-06-30 2014-12-18 Nal Pharmaceuticals, Ltd. Transdermal drug delivery system containing donepezil
PT2598119T (pt) 2010-07-29 2018-12-17 Allergan Inc Soluções de brimonidina e timolol isentas de conservantes
AU2011316565A1 (en) 2010-10-12 2013-05-02 Cerecor Inc. Antitussive compositions comprising memantine
JP5699554B2 (ja) 2010-11-11 2015-04-15 富士通株式会社 ベクトル処理回路、命令発行制御方法、及びプロセッサシステム
BR112013012156A2 (pt) 2010-11-17 2017-12-05 Hexal Ag sistema terapêutico transdérmico e método de produção de um sistema terapêutico transdérmico
WO2012084969A1 (en) 2010-12-22 2012-06-28 Hexal Ag Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition
EA201390980A1 (ru) * 2010-12-29 2013-11-29 Фармафилм С.Р.Л. Лекарственный пластырь для улучшенного трансдермального проникновения диклофенака диэтиламмония
CN102775476B (zh) * 2011-05-12 2015-01-07 上海天伟生物制药有限公司 一种米卡芬净钠盐的制备方法
US8673338B2 (en) 2011-07-29 2014-03-18 Massachusetts Eye And Ear Infirmary Methods of delivering pharmaceutical agents
JP5808214B2 (ja) * 2011-09-30 2015-11-10 株式会社トクヤマ 貼付剤
KR101239150B1 (ko) 2012-02-28 2013-03-06 에스케이케미칼주식회사 도네페질-함유 경피흡수제제 및 그의 제조방법
US9408802B1 (en) * 2012-03-22 2016-08-09 Prosolus, Inc. Seven day drug in adhesive transdermal delivery
US9145907B2 (en) 2012-08-28 2015-09-29 Hsiutao Liang Pipe connector
US20140256690A1 (en) 2013-03-08 2014-09-11 Agile Therapeutics, Inc. Contraceptive method
WO2014174564A1 (ja) 2013-04-22 2014-10-30 祐徳薬品工業株式会社 メマンチン含有経皮吸収型貼付製剤
JP5415645B1 (ja) 2013-06-28 2014-02-12 久光製薬株式会社 貼付剤の製造方法、貼付剤及び包装体
EP3038608B1 (en) * 2013-08-30 2018-01-03 3M Innovative Properties Company Estradiol containing transdermal drug delivery systems and compositions
CA2924231C (en) 2013-10-07 2018-04-03 Teikoku Pharma Usa, Inc. Dexmedetomidine transdermal delivery devices and methods for using the same
WO2015053878A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
EP3069712B1 (en) * 2013-11-17 2020-09-23 MEDRx Co., Ltd. Transdermal colloidal solution agent
KR101485822B1 (ko) 2014-01-22 2015-01-23 주식회사 대웅제약 도네페질 또는 그의 염을 함유하는 경피흡수제제
JP2015151370A (ja) * 2014-02-14 2015-08-24 日東電工株式会社 貼付製剤
CN106659702A (zh) 2014-06-24 2017-05-10 Kat皮肤传导公司 透皮递送体系
US10071090B2 (en) * 2014-07-18 2018-09-11 Buzzz Pharmaceuticals Limited Oxymorphone transdermal patch
US10925936B2 (en) 2014-09-03 2021-02-23 Nitto Denko Corporation Vaccine pharmaceutical composition for cell-mediated immunity containing bisphosphonates
WO2016046675A1 (en) 2014-09-28 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of neurological diseases
ES2786399T3 (es) 2014-12-18 2020-10-09 Icure Pharm Inc Preparación transdérmica que contiene donepezilo como principio activo
WO2016122806A1 (en) 2015-01-28 2016-08-04 Dnx Biotech, Llc Compositions and methods of using a soluble tnf-alpha receptor modified for increased half-life
JP2018518502A (ja) 2015-06-22 2018-07-12 コリウム インターナショナル， インコーポレイテッド 難溶性治療剤を含む経皮接着性組成物
JP6462880B2 (ja) 2015-07-27 2019-01-30 久光製薬株式会社 アセナピン含有貼付剤の製造方法
IL303255A (en) * 2015-12-30 2023-07-01 Corium Inc Systems and methods for long term transdermal administration
CN105693556A (zh) * 2016-03-01 2016-06-22 巴斯特医药科技（常州）有限公司 卡巴拉汀酒石酸盐的转化方法及其产物制成的贴片
JP7174632B2 (ja) 2016-06-23 2022-11-17 コリウム， インコーポレイテッド 親水性ドメインおよび疎水性ドメインならびに処置剤との接着剤マトリックス
KR102508993B1 (ko) 2016-07-27 2023-03-10 코리움, 인크. 메만틴 경피 송달 시스템
KR102406536B1 (ko) 2016-07-27 2022-06-08 코리움, 인크. 도네페질 경피 전달 시스템
WO2018022814A1 (en) 2016-07-27 2018-02-01 Corium International, Inc. Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
CA3071007A1 (en) 2017-07-26 2019-01-31 Corium, Inc. Transdermal delivery system with a microporous membrane having solvent-filled pores

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007129427A1 (ja) 2006-05-08 2007-11-15 Teikoku Seiyaku Co., Ltd. 抗認知症薬物の経皮吸収製剤
JP2007302582A (ja) 2006-05-09 2007-11-22 Hisamitsu Pharmaceut Co Inc ドネペジル経皮吸収型製剤
WO2008066179A1 (en) 2006-12-01 2008-06-05 Nitto Denko Corporation Percutaneous absorption preparation
JP2011513447A (ja) 2008-03-11 2011-04-28 エルテーエス ローマン テラピー−ジステーメ アーゲー 安定化された膜を有する経皮治療システム
JP2013528631A (ja) 2010-06-17 2013-07-11 エルテーエス ローマン テラピー−ジステーメ アーゲー メマンチンの経皮投与
JP2014502639A (ja) 2011-01-12 2014-02-03 タイワン バイオテック カンパニー リミテッド ドネペジル経皮吸収型パッチ及びアルツハイマー病の治療方法

Also Published As

Publication number Publication date
US20250375396A1 (en) 2025-12-11
KR102545649B1 (ko) 2023-06-22
AU2017302307A1 (en) 2019-02-14
AU2025205205A1 (en) 2025-07-24
US20180028463A1 (en) 2018-02-01
KR20230109782A (ko) 2023-07-20
US20240156747A1 (en) 2024-05-16
RU2019105279A3 (enExample) 2020-12-23
US10307379B2 (en) 2019-06-04
AU2017301928B2 (en) 2023-04-06
CA3031945C (en) 2025-09-23
MX2022006681A (es) 2022-07-11
JP7071330B2 (ja) 2022-05-18
US20220016045A1 (en) 2022-01-20
WO2018022815A2 (en) 2018-02-01
WO2018022815A3 (en) 2018-03-08
EP3490541A2 (en) 2019-06-05
JP2019525932A (ja) 2019-09-12
KR20190032512A (ko) 2019-03-27
AU2023203618B2 (en) 2025-09-18
AU2023203616A1 (en) 2023-07-06
WO2018022817A1 (en) 2018-02-01
JP2019523270A (ja) 2019-08-22
KR20230097203A (ko) 2023-06-30
WO2018022816A1 (en) 2018-02-01
CN109789105B (zh) 2022-12-27
US20190247320A1 (en) 2019-08-15
US20180028663A1 (en) 2018-02-01
CA3031945A1 (en) 2018-02-01
KR20190034601A (ko) 2019-04-02
CA3032148A1 (en) 2018-02-01
KR102545643B1 (ko) 2023-06-21
CN109789105A (zh) 2019-05-21
JP2022093707A (ja) 2022-06-23
JP2022140751A (ja) 2022-09-27
JP7153010B2 (ja) 2022-10-13
CN109789106A (zh) 2019-05-21
CN116966166A (zh) 2023-10-31
MX2019001103A (es) 2019-09-27
SG11201900692WA (en) 2019-02-27
EP3490558A1 (en) 2019-06-05
EP3490541B1 (en) 2025-07-09
KR20190035801A (ko) 2019-04-03
MX394249B (es) 2025-03-24
US9993466B2 (en) 2018-06-12
US20180028462A1 (en) 2018-02-01
KR102555208B1 (ko) 2023-07-17
CA3032044C (en) 2024-10-01
US11103463B2 (en) 2021-08-31
KR20220082928A (ko) 2022-06-17
JP2019523268A (ja) 2019-08-22
JP2022121629A (ja) 2022-08-19
KR20220082098A (ko) 2022-06-16
US20250375395A1 (en) 2025-12-11
KR102406536B1 (ko) 2022-06-08
AU2023204240A1 (en) 2023-07-27
US10300025B2 (en) 2019-05-28
US20180028512A1 (en) 2018-02-01
US20250325496A1 (en) 2025-10-23
CN109789133A (zh) 2019-05-21
KR102406528B1 (ko) 2022-06-08
CN109789106B (zh) 2023-06-27
US20210015761A1 (en) 2021-01-21
AU2023203618A1 (en) 2023-07-06
KR102406482B1 (ko) 2022-06-08
RU2019105279A (ru) 2020-08-27
US20180235901A1 (en) 2018-08-23
AU2017301928A1 (en) 2019-02-14
CA3032044A1 (en) 2018-02-01
CN116270551A (zh) 2023-06-23
KR20230098349A (ko) 2023-07-03
US20190247321A1 (en) 2019-08-15
AU2017302306A1 (en) 2019-02-14
EP3490540A1 (en) 2019-06-05
KR20220082929A (ko) 2022-06-17

Similar Documents

Publication Publication Date Title
JP7251033B2 (ja) ドネペジル経皮送達システム
US20240041791A1 (en) Transdermal adhesive composition comprising a poorly soluble therapeutic agent
JP7611327B2 (ja) 溶媒充填細孔を有する微多孔膜を有する経皮送達システム
KR102508993B1 (ko) 메만틴 경피 송달 시스템
JP2024522910A (ja) コロナ放電処理された経皮送達システム
US20240082172A1 (en) Method for depot creation during transdermal drug delivery
RU2779471C2 (ru) Трансдермальная система доставки донепезила
JP2024523620A (ja) 経皮送達システムを用いた併用療法
KR102904873B1 (ko) 용매가 채워진 공극을 가진 미세다공성 막을 구비한 경피 전달 시스템
RU2789194C2 (ru) Система чрескожной доставки с помощью микропористой мембраны, содержащей заполненные растворителем поры

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210624

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210924

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220630

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220630

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220711

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220815

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230302

R150 Certificate of patent or registration of utility model

Ref document number: 7251033

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150